Cancer cachexia syndrome: Pathogenesis, diagnosis, and new therapeutic options

Nutrition and Cancer

Volumn 67, Issue 1, 2015, Pages 12-26

  Mondello, Patrizia ^a   Mian, Michael ^b,c   Aloisi, Carmela ^d   Famà, Fausto ^a   Mondello, Stefania ^a   Pitini, Vincenzo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b Department of Hematology and CTMO Bolzano ^*  (Italy)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; APPETITE STIMULANT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CANNABINOID; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ENOBOSARM; GAMMA INTERFERON; GESTAGEN; GHRELIN; INSULIN; INSULIN SENSITIZING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; LIPID MOBILIZING FACTOR; OBESTATIN; OXANDROLONE; PROTEOLYSIS INDUCING FACTOR; SELECTIVE ANDROGEN RECEPTOR MODULATOR; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CACHEXIA; CORTICOSTEROID THERAPY; ENTERIC FEEDING; FOOD INTAKE; HORMONE ACTION; HUMAN; INSULIN RESISTANCE; NONHUMAN; PARENTERAL NUTRITION; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TREATMENT PLANNING; ANIMAL; DISEASE MODEL; METABOLISM; MULTIMODALITY CANCER THERAPY; PARANEOPLASTIC SYNDROMES; PROGNOSIS;

ANIMALS; CACHEXIA; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; HUMANS; PARANEOPLASTIC SYNDROMES; PROGNOSIS;

EID: 84920537645     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2015.976318     Document Type: Article

References (200)

1. Baracos VE: Hypercatabolism and hypermetabolism in wasting states. Curr Opin Clin Nutr Metab Care 5, 237-239, 2002.
2. Muliawati Y, Haroen H, and Rotty LW: Cancer anorexia-cachexia syndrome. Acta Med Indones 44, 154-162, 2012.
3. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, et al.: Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12, 489-495, 2011.
4. Tisdale MJ: Cachexia in cancer patients. Nature Reviews Cancer 2, 862-871, 2002.
5. Bennani-Baiti N and Walsh D: What is cancer anorexia-cachexia syndrome? A historical perspective. J R Coll Physicians Edinb 39, 257-262, 2009.
6. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69, 491-497, 1980.
7. Scarpi E, Maltoni M, Miceli R, Mariani L, Caraceni A, et al.: Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of delirium. Oncologist 16, 1793-1799, 2011.
8. Mercadante S, Valle A, Porzio G, Aielli F, Adile C, et al.: Prognostic factors of survival in patients with advanced cancer admitted to home care. J Pain Symptom Manage 45, 56-62, 2013.
9. Gordon JN, Green SR, and Goggin PM: Cancer cachexia. Q J Med 98, 779-788, 2005.
10. Baiti NB and Davis MP: Cytokines and cancer anorexia cachexia syndrome. Am J Hospice & Paliative Med 25, 407-411, 2008.
11. Plata-Salam-An CR: Cytokines and feeding. Int J Obes Relat Metab Disord 25(Suppl 5), S48-S52, 2001.
12. Laviano A, Inui A, and Marks DL: Neural control of the anorexiacachexia syndrome. Am J Physiol Endocrinol Metab 295, 1000-1008, 2008.
13. Schwarts MW, Woods SC, Porte D Jr, Seeley RJ, and Baskin DG: Central nervous system control of food intake. Nature 404(6778), 661-671, 2000.
14. Makarenco JG, Meguid MM, Gatto L, Chen C, and Ugrumov MV: Decreased NPY innervations of the hypothalamic nuclei in rats with cancer anorexia. Brain Res 961, 100-108, 2003.
15. Marks DL, Ling N, and Cone RD: Role of the central melanocortin system in cachexia. Cancer Res 61, 1432-1438, 2001.
16. Plata-Salaman CR, Ilyin SE, and Gaylr D: Brain cytokine m RNA in anoretic rats bearing prostate adenocarcinoma tumour cells. Am J Physiol 275(2, Pt 2), R566-R573, 1998.
17. Marks DL, Butler AA, Turner R, Brookhart G, and Cone RD: Differential role of melanocortin receptor subtypes in cachexia. Endocrinology 144, 1513-1523, 2003.
18. Fearon KC, Glass DJ, and Guttridge DC: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 16, 153-166, 2012.
19. Deans C and Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metal Care 8, 265-269, 2005.
20. Jager A, Sleijfer S, and van der Rijt CC: The pathogenesis of cancer related fatigue: Could increased activity of pro-inflammatory cytokines be the common denominator? Eur J Cancer 44, 175-181, 2008.
21. Inui A: Cancer anorexia-cachexia syndrome: Are neuropetides the key? Cancer Res 59, 4493-4501, 1999.
22. Shintani F, Kanba S, Nakaki T, Nibuya M, Kinoshita N, et al.: Interleukin-1 beta augments release of norepinephrine, dopamine and serotonin in the rat anterior hypothamus. J Neurosci 13, 3574-3581, 1993.
23. Bl-Aha V, Yang ZJ, Meguid MM, Chai JK, Oler A, et al.: Ventromedial nucleus of hypothalamus is related to the development of cancer-induced anorexia: In vivo microdialysis study. Acta Medica (Hradec Kralove) 41, 3-11, 1998.
24. Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, et al.: Muscle wasting in cancer cachexia: Clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med 62, 265-279, 2011.
25. Julienne CM, Dumas JF, Goupille C, Pinault M, Berri C, et al.: Cancer cachexia is associated with a decrease in skeletal muscle mitochondrial oxidative capacities without alteration of ATP production efficiency. J Cachexia Sarcopenia Muscle 3, 265-275, 2012.
26. Sun YS, Ye ZY, Qian ZY, Xu XD, and Hu JF: Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients. J Exp Clin Cancer Res 31, 81, 2012.
27. Laviano A, Meguid MM, Inui A, Muscaritoli M, and Rossi-Fanelli F: Therapy insight: cancer anorexia-cachexia syndrome-When all you can eat is yourself. Nat Clin Pract Oncol 2, 158-165, 2005.
28. Langhans W: Peripheral mechanisms involved with catabolism. Curr Opin Clin Nutr Metab Care 5, 419-426, 2002.
29. Russell ST, Siren PM, Siren MJ, and Tisdale MJ: Attenuation of skeletal muscle atrophy in cancer cachexia by D-myo-inositol 1,2,6-Triphosphate. Cancer Chemother Pharmacol 64, 517-527, 2009.
30. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, et al.: Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 114, 370-378, 2004.
31. Suh SY, Choi YS, Yeom CH, Kwak SM, Yoon HM, et al.: Interleukin-6 but not tumour necrosis factor-Alpha predicts survival in patients with advanced cancer. Support Care Cancer 21, 3071-3077, 2013
32. Moses AG, Maingay J, Sangster K, Fearon KC, and Ross JA: Proinflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol Rep 21, 1091-1095, 2009.
33. Tisdale MJ: Mechanisms of cancer cachexia. Physiol Rev 89, 381-410, 2009.
34. Kwak KS, Zhou X, Solomon V, Baracos VE, Davis J, et al.: Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alphaiI during cancer cachexia. Cancer Res 64, 8193-8198, 2004.
35. Strassmann G, Masui Y, Chizzonite R, and Fong M: Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor. J Immunol 150, 2341-2345, 1993.
36. Ohe Y, Podack ER, Olsen KJ, Miyahara Y, Miura K, et al.: Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice. Br J Cancer 67, 939-944, 1993.
37. Ando K, Takahashi F, Motojima S, Nakashima K, Kaneko N, et al.: Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol, 31, E69-E72, 2013.
38. Shibata M, Nagata Y, Kimura T, Kanou H, Nezu T, et al. Elevated serum concentration of interleukin-1 receptor antagonist (IL-1ra) is correlated to interleukin-6 and to hypoalbuminemia in cachectic patients with colorectal cancer. Jnt J Clin Oncol 5, 116-120, 2000.
39. Martignoni ME, Kunze P, and Friess H: Cancer cachexia. Molecular Cancer 2, 36, 2003.
40. Whitaker KW and Reyes TM: Central blockade of melanocortin receptors attenuates the metabolic and locomotor responses to peripheral interleukin-1beta administration. Neuropharmacology 54, 509-520, 2008.
41. Cooney R, Owens E, Jurasinski C, Gray K, Vannice J, et al.: Interleukin-1 receptor antagonist prevents sepsis-induced inhibition if protein synthesis. Am J Physiol 267(5 Pt 1), E636-E641, 1994.
42. Hochstrasser M: Origin and function of ubiquitin-like proteins. Nature 458, 422-429, 2009.
43. Di Marco S, Mazroui R, Dallaire P, Chittur S, Tenenbaum SA, et al.: NF-kappa B-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release. Mol Cell Biol 25, 6533-6545, 2005.
44. Ramamoorthy S, Donohue M, and Buck M: Decreased Jun-D and myogenin expression in muscle wasting of human cachexia. Am J Physiol Endocrinol Metab 297, E392-E401, 2009.
45. Matthys P, Dijkmans R, Proost P, Van Damme J, Heremans H, et al.: Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells. Int J Cancer 49, 77-82, 1991.
46. Llovera M, Carb-o N, L-opez-Soriano J, Garcia-Martinez C, Busquets S, et al.: Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett 133, 83-87, 1998.
47. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, et al.: Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 114, 370-378, 2004.
48. Ravasco P, Monteiro-Grillo I, and Camilo M: How relevant are cytokines in colorectal cancer wasting?. Cancer J 13, 392-398, 2007.
49. Martin F, Santolaria F, Batista N, Milena A, Gonzalez-Reimers E, et al.: Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11, 80-86, 1999.
50. Smith MA, Moylan JS, Smith JD, Li W, and Reid MB: IFN-gamma does not mimic the catabolic effects of TNF-Alpha. Am J Physiol Cell Physiol 293, C1947-C1952, 2007.
51. Moldawer LL and Copeland EM: Proinflammatory cytokines, nutritional support and the cachexia syndrome. Cancer (Phila.) 79, 1828-1839, 1997.
52. Licinio J and Wong M-L: Pathways and mechanisms for cytokine signaling of the central nervous system. J Clin Investig 100, 2941-2947, 1997.
53. Noguchi Y, Yoshikawa T, Matsumoto A, Svaninger G, and Gelin J: Are cytokines possible mediators of cancer cachexia?. Surg Today 26, 467-475, 1996.
54. Tisdale MJ: Molecular pathways leading to cancer cachexia. Physiology (Bethesda) 20, 340-348, 2005.
55. MacDonald N, Easson AM, Mazurak VC, Dunn GP, and Baracos VE: Understanding and managing cancer cachexia. J Am Coll Surg 197, 143-161, 2003.
56. Mirza KA and Tisdale MJ: Role of Ca(2C) in proteolysis-inducing factor (PIF)-induced atrophy of skeletal muscle. Cell Signal 24, 2118-2122, 2012.
57. Khan S and Tisdale MJ: Catabolism of adipose tissue by a tumour-produced lipid-mobilising factor. Int J Cancer 80, 444-447, 1999.
58. Islam-Ali B, Khan S, Price SA, and Tisdale MJ: Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF). Br J Cancer 85, 758-763, 2001.
59. Banks WA and Farrell CL: Impaired transport of leptin across the bloodbrain barrier in obesity is acquired and reversible. Am J Physiol Endocrinol Metab 285, E10-E15, 2003.
60. Margetic S, Gazzola C, Pegg GG, and Hill RA: Leptin: A review of its peripheral actions and interactions. Int J Obes Relat Metab Disord 26, 1407-1433, 2002.
61. Horvath TL, Naftolin F, Kalra SP, and Leranth C: Neuropeptide-Y innervation of beta-endorphin-containing cells in the rat mediobasal hypothalamus: a light and electron microscopic double immunostaining analysis. Endocrinology 131, 2461-2467, 1992.
62. Diano S: New aspects of melanocortin signaling: A role for PRCP in a-MSH degradation. Front Neuroendocrinol 32, 70-83, 2011.
63. Friedman JM: A tale of two hormones. Nat Med 16, 1100-1106, 2010.
64. Mantovani G, Macci-o A, Mura L, Massa E, Mudu MC, et al.: Serum levels of leptin and proinflammatory cytokines in patients with advancedstage cancer at different sites. J Mol Med (Berl) 78, 554-561, 2000.
65. Bing C, Taylor S, Tisdale MJ, and Williams G: Cachexia in MAC16 adenocarcinoma: suppression of hunger despite normal regulation of leptin, insulin and hypothalamic neuropeptide Y. J Neurochem 79, 1004-1012, 2001.
66. Schwartz MW and Morton GJ: Obesity: Keeping hunger at bay. Nature 418, 595-597, 2002.
67. Grunfeld C, Zhao C, Fuller J, Pollack A, Moser A, et al.: Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Invest 97, 2152-2157, 1996.
68. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, et al.: Abnormal splicing of the leptin receptor in diabetic mice. Nature 379, 632-635, 1996.
69. Lacquaniti A, Donato V, Chirico V, Buemi A, and Buemi M: Obestatin: An interesting but controversial gut hormone. Ann Nutr Metab 59, 193-199, 2011.
70. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, et al.: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334, 292-295, 1996.
71. Korbonits M, Goldstone AP, GueorguievM, and Grossman AB: Ghrelin-A hormone with multiple functions. Front Neuroendocrinol 25, 27-68, 2004.
72. Karapanagiotou EM, Polyzos A, Dilana KD, Gratsias I, Boura P, et al.: Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients. Lung Cancer 66, 393-398, 2009.
73. Kim HJ, Kim HJ, Yun J, Kim KH, Kim SH, et al.: Pathophysiological role of hormones and cytokines in cancer cachexia. J Korean Med Sci 27, 128-134, 2012.
74. DeBoer MD, Zhu XX, Levasseur P, Meguid MM, Suzuki S, et al.: Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 148, 3004-3012, 2007.
75. Northrup R, Kuroda K, Duus EM, Barnes SR, Cheatham L, et al.: Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Support Care Cancer 21, 2409-2415, 2013.
76. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, et al.: Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89, 2832-2836, 2004
77. Garcia JM, Friend J, and Allen S: Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 21, 129-137, 2013.
78. Nakahara T, Harada T, Yasuhara D, Shimada N, Amitani H, et al.: Plasma obestatin concentrations are negatively correlated with body mass index, insulin resistance index, and plasma leptin concentrations in obesity and anorexia nervosa. Biol Psychiatry 64, 252-255, 2008.
79. Diez JJ and Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148, 293-300, 2003.
80. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, et al.: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86, 3815-3819, 2001.
81. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, et al.: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257, 79-83, 1999.
82. Staiger H, Tschritter O, Machann J, Thamer C, Fritsche A, et al.: Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Obes Res 11, 368-372, 2003.
83. Berg AH, Combs TP, and Scherer PE: ACRP30/adiponectin: An adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13, 84-89, 2002.
84. Gulen ST, Karadag F, Karul AB, Kilicarslan N, Ceylan, et al.: Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung 190, 327-332, 2012.
85. Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, et al.: Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab 88, 993-997, 2003.
86. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, et al.: Prostate cancer and adiponectin. Urology 65, 1168-1172, 2005.
87. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, et al.: Plasma adiponectin and gastric cancer. Clin Cancer Res 11, 466-472, 2005.
88. Wolf I, Sadetzki S, Kanety H, Kundel Y, Pariente C, et al.: Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer 106, 966-973, 2006.
89. Kemik O, Sumer A, Kemik AS, Hasirci I, Purisa S, et al.: The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J Surg Oncol 8, 85, 2010.
90. Wang B, Jenkins JR, and Trayhurn P: Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-Alpha. Am J Physiol Endocrinol Metab 288, E731-E740, 2005.
91. Tayek JA: A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr 11, 445-456, 1992.
92. Parekh N, Lin Y, Hayes RB, Albu JB, and Lu-Yao GL: Longitudinal associations of blood markers of insulin and glucose metabolism and cancer mortality in the third National Health and Nutrition Examination Survey. Cancer Causes Control 21, 631-642, 2010.
93. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, and Karasik A: Tumor necrosis factor-Alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 268, 26055-26058, 1993.
94. Jasani B, Donaldson LJ, Ratcliffe JG, and Sokhi GS: Mechanism of impaired glucose tolerance in patients with neoplasia. Br J Cancer 38, 287-292, 1978.
95. Norton JA, Maher M, Wesley R, White D, and Brennan MF: Glucose intolerance in sarcoma patients. Cancer 54(12), 3022-3027, 1984.
96. Lecker SH, Goldberg AL, and Mitch WE: Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 17, 1807-1819, 2006.
97. Louard RJ, Fryburg DA, Gelfand RA, and Barrett EJ: Insulin sensitivity of protein and glucose metabolism in human forearm skeletal muscle. J Clin Invest 90, 2348-2354, 1992.
98. Gelfand RA and Barrett EJ: Effect of physiologic hyperinsulinemia on skeletal muscle protein synthesis and breakdown in man. J Clin Invest 80, 1-6, 1987.
99. Couch M, Lai V, Cannon T, Guttridge D, Zanation A, et al.: Cancer cachexia syndrome in head and neck cancer patients: part 1. diagnosis, impact on quality of life and survival, and treatment. Head & Neck 29, 401-411, 2007.
100. Inui A: Cancer anorexia-cachexia syndrome: Current issues in research and management. CA Cancer J Clin 52, 72-91, 2002.
101. Punzi T, Fabris A, Morucci G, Biagioni P, Gulisano M, et al.: C-reactive protein levels and vitamin d receptor polymorphisms as markers in predicting cachectic syndrome in cancer patients. Mol Diagn Ther 16, 115-124, 2012.
102. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, et al.: Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clin Chem Lab Med 46, 359-364, 2008.
103. McMillan DC: An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 67, 257-262, 2008.
104. Mantovani G, Macci-o A, Madeddu C, Serpe R, Massa E, et al.: Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 15, 200-211, 2010.
105. Macci-o A, Madeddu C, Gramignano G, Mulas C, Floris C, et al.: A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: Evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 124, 417-425, 2012.
106. Richards CH, Roxburgh CS, MacMillan MT, Isswiasi S, Robertson EG, et al.: The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS One 7(8), e41883, 2012.
107. Proctor MJ, Horgan PG, Talwar D, Fletcher CD, Morrison DS, et al.: Optimization of the systemic inflammation-based Glasgow prognostic score: A Glasgow Inflammation Outcome Study. Cancer 119, 2325-2332, 2013.
108. Argil-es JM, L-opez-Soriano FJ, Toledo M, Betancourt A, Serpe R, et al.: The cachexia score (CASCO): A new tool for staging cachectic cancer patients. J Cachexia Sarcopenia Muscle 2, 87-93, 2011.
109. Baracos VE, Reiman T, Mourtzakis M, Gioulbasanis I, and Antoun S: Body composition in patients with non-small cell lung cancer: A contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 91, 1133S-1137S, 2010.
110. Di Sebastiano KM, Yang L, Zbuk K, Wong RK, Chow T, et al.: Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: The relationship with diabetes and anaemia. Br J Nutr 109, 302-312, 2013.
111. Argil-es JM, Olivan M, Busquets S, and L-opez-Soriano FJ: Optimal management of cancer anorexia-cachexia syndrome. Cancer Manag Res 2, 27-38, 2010.
112. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 12, 489-495, 2011.
113. Prado CM, Sawyer MB, Ghosh S, Lieffers JR, Esfandiari N, et al.: Central tenet of cancer cachexia therapy: Do patients with advanced cancer have exploitable anabolic potential?. Am J Clin Nutr 98, 1012-1019, 2013.
114. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, et al.: Prognostic factors in advanced cancer patients: Evidence-based clinical recommendations-A study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23, 6240-6248, 2005.
115. Madeddu C, Maccio A, and Mantovani G: Multitargeted treatment of cancer cachexia. Crit Rev Oncog 17, 305-314, 2012.
116. Foster AC, Chen C, Markison S, and Marks DL: MC4 receptor antagonists: A potential treatment for cachexia. Drugs 8, 314-319, 2005.
117. Springer J, Tschirner A, Hartman K, Palus S, Wirth EK, et al.: Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. Int J Cancer 131, 2187-2196, 2012.
118. Boddaert MS, Gerritsen WR, and Pinedo HM: On our way to targeted therapy for cachexia in cancer?. Curr Opin Oncol 18, 335-340, 2006.
119. Bosaeus I: Nutritional support in multimodal therapy for cancer cachexia. Support Care Cancer 16, 447-451, 2008.
120. Meijerink WJ, von Meyenfeldt MF, Rouflart MM, and Soeters PB: Efficacy of perioperative nutritional support. Lancet 340, 187-188, 1992.
121. Hyltander A, Bosaeus I, Svedlund J, Liedman B, Hugosson I, et al.: Supportive nutrition on recovery of metabolism, nutritional state, healthrelated quality of life, and exercise capacity after major surgery: A randomized study. Clin Gastroenterol Hepatol 3, 466-474, 2005.
122. August DA, Huhmann MB, and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors: A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr 33, 472-500, 2009.
123. Shih A and Jackson KC 2nd: Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother 21(4), 69-76, 2007.
124. Barber MD, Ross JA, and Fearon KC: Cancer cachexia. Surg Oncol 8(3), 133-141, 1999.
125. Popiera T, Lucchi R, and Giongo F: Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol 25, 1823-1829, 1989.
126. Sarcev T, Secen N, Sabo A, and Povazan D: Influence of dexamethasone on appetite and body weight in lung cancer patients. Med Pregl 61, 571-575, 2008.
127. Melstrom LG, Melstrom KA Jr, Ding XZ, and Adrian TE: Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histol Histopathol 22, 805-814, 2007.
128. Demoor-Goldschmidt C and Raynard B: How can we integrate nutritional support in medical oncology?. Bull Cancer 96, 665-675, 2009.
129. Mantovani G, Macci-o A, Bianchi A, Curreli L, Ghiani M, et al.: Megestrol acetate in neoplastic anorexia/cachexia: Clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 25, 135-141, 1995.
130. Mantovani G, Maccio A, Massa E, and Madeddu C: Managing cancerrelated anorexia/cachexia. Drugs 61(4), 499-514, 2001.
131. Berenstein EG and Ortiz Z: Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev, CD004310, 2005.
132. Simons JP, Schols AM, Hoefnagels JM, Westerterp KR, ten Velde GP, et al.: Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: A randomized, placebo-controlled trial. Cancer 82, 553-560, 1998.
133. Loprinzi CL, Bernath AM, Schaid DJ, Malliard JA, Athmann LM, et al.: Phase III evaluation of 4 doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Oncology 51(Suppl 1), 2-7, 1994.
134. Downer S, Joel S, Allbright A, Plant H, Stubbs L, et al.: A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer 67, 1102-1105, 1993.
135. Neri B, Garosi VL, and Intini C: Effect of medroxyprogesterone acetate on the quality of life of the oncologic patient: A multicentric cooperative study. Anticancer Drugs 8, 459-465, 1997.
136. Madeddu C, Macci-o A, Panzone F, Tanca FM, and Mantovani G: Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opin Pharmacother 10, 1359-1366, 2009.
137. Bruera E, Ernst S, Hagen N, Spachynski K, Belzile M, et al.: Effectiveness of megestrol acetate in patients with advanced cancer: A randomised, doubleblind, crossover study. Cancer Prev Control 2, 74-78, 1998.
138. Vadell C, Segui MA, Gim-enez-Arnau JM, Morales S, Cirera L, et al.: Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am J Clin Oncol 21, 347-351, 1998.
139. Rowland KM Jr, Loprinzi CL, Shaw EG, Maksymiuk AW, Kuross SA, et al.: Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 14, 135-141, 1996.
140. Martin BR and Wiley JL: Mechanism of action of cannabinoids: How it may lead to treatment of cachexia, emesis, and pain. J Support Oncol 2, 305-314, 2004.
141. Engeli S: Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol 209, 357-381, 2012.
142. Gamage TF and Lichtman AH: The endocannabinoid system: Role in energy regulation. Pediatr Blood Cancer 58, 144-148, 2012.
143. Tchekmedyian NS, Hickman M, Siau J, Greco FA, Keller J, et al.: Megestrol acetate in cancer anorexia and weight loss. Cancer 69, 1268-1274, 1992.
144. Cannabisin-Cachexia-Study-Group, Strasser F, Luftner D, Possinger K, Ernst G, et al.: Comparison of orally administered cannabis extract and delta-9-Tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabisin-Cachexia-Study-Group. J Clin Oncol 24, 3394-3400, 2006.
145. Gao W, Kim J, and Dalton JT: Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm Res 23, 1641-1658, 2006.
146. Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, et al.: Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 85, 4908-4911, 2000.
147. Akamizu T, Takaya K, Irako T, Hosoda H, Teramukai S, et al.: Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur J Endocrinol 150, 447-455, 2004.
148. Wu R, Dong W, Zhou M, Zhang F, Marini CP, et al.: Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats. Am J Respir Crit Care Med 176, 805-813, 2007.
149. Gonzalez-Rey E, Chorny A, and Delgado M: Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 130, 1707-1720, 2006.
150. Nagaya N, Kojima M, and Kangawa K: Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-Associated cachexia. Intern Med 45, 127-134, 2006.
151. Temel J, Bondarde S, Jain M, Allen S, and Mann W: Efficacy and Safety of Anamorelin HCl in NSCLC Patients: Results from a randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study. European Cancer Congress. Amsterdam, The Netherlands, 2013, p. 1308.
152. Keifer JA, Guttridge DC, Ashburner BP, and Baldwin AS Jr: Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276, 22382-22387, 2001.
153. Jin SH, Kim TI, Han DS, Shin SK, and Kim WH: Thalidomide suppresses the interleukin 1betainduced NFkappaB signaling pathway in colon cancer cells. Ann N Y Acad Sci 973, 414-418, 2002.
154. Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K, and Dannenberg AJ: Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 7, 3349-3355, 2001.
155. Tassinari D, Santelmo C, Tombesi P, and Sartori S: Thalidomide in the treatment of cancer cachexia. J Palliat Care 24, 187-189, 2008.
156. Reid J, Mills M, Cantwell M, Cardwell CR, Murray LJ, et al.: Thalidomide for managing cancer cachexia. Cochrane Database Syst Rev 4, CD008664, 2012.
157. Davis M, Lasheen W, Walsh D, Mahmoud F, Bicanovsky L, et al.: A Phase II dose titration study of thalidomide for cancer-Associated anorexia. J Pain Symptom Manage 43, 78-86, 2012.
158. Yennurajalingam S, Willey JS, Palmer JL, Allo J, Del Fabbro E, et al.: The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. J Palliat Med 15, 1059-1064, 2012.
159. Wilkes EA, Selby AL, Cole AT, Freeman JG, Rennie MJ, et al.: Poor tolerability of thalidomide in end-stage oesophageal cancer. Eur J Cancer Care (Engl) 20, 593-600, 2011.
160. Mantovani G: Randomised phase III clinical trial of five different arms of treatment on 332 patients with cancer cachexia. Eur Rev Med Pharmacol Sci 14, 292-301, 2010.
161. Mantovani G, Macci-o A, Madeddu C, Gramignano G, Lusso MR, et al.: A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/ cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev 15, 1030-1034, 2006.
162. Mantovani G, Macci-o A, Madeddu C, Serpe R, Antoni G, et al.: Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med (Berl) 88, 85-92, 2010.
163. Lundholm K, Keorner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, et al.: Insulin treatment in cancer cachexia: Effects on survival, metabolism, and physical functioning. Clin Cancer Res 13, 2699-2706, 2007.
164. Lazarus DD, Kambayashi T, Lowry SF, and Strassmann G: The lack of an effect by insulin or insulin-like growth factor-1 in attenuating colon-2-mediated cancer cachexia. Cancer Lett 103, 71-77, 1996.
165. Pearlstone DB, Wolf RF, Berman RS, Burt M, and Brennan MF: Effect of systemic insulin on protein kinetics in postoperative cancer patients. Ann Surg Oncol 1, 321-332, 1994.
166. Asp ML, Tian M, Wendel AA, and Belury MA: Evidence for the contribution of insulin resistance to the development of cachexia in tumorbearing mice. Int J Cancer 126, 756-763, 2009.
167. Yki-Jearvinen H: Thiazolidinediones. N Engl JMed 351, 1106-1118, 2004.
168. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, et al.: Metformin increases AMP-Activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51, 2074-2081, 2002.
169. Diamanti-Kandarakis E, Economou F, Palimeri S, and Christakou C: Metformin in polycystic ovary syndrome. Ann N Y Acad Sci 1205, 192-198, 2010.
170. Miyazaki Y, He H, Mandarino LJ, and DeFronzo RA: Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 52, 1943-1950, 2003.
171. Schenk S, Saberi M, and Olefsky JM: Insulin sensitivity: Modulation by nutrients and inflammation. J Clin Invest 118, 2992-3002, 2008.
172. Hauner H: The mode of action of thiazolidinediones. Diabetes Metab Res Rev 18(Suppl), S10-S15, 2002.
173. Chen SZ and Xiao JD: Rosiglitazone and imidapril alone or in combination alleviate muscle and adipose depletion in a murine cancercachexia model. Tumour Biol 35, 323-332, 2014.
174. Kintscher U and Law RE: PPARg-mediated insulin sensitization: The importance of fat versus muscle. Am J Physiol Endocrinol Metab 288, E287-E291, 2005.
175. Busquets S, Figueras MT, Fuster G, Almendro V, Moore-Carrasco R, et al.: Anticachectic effects of formoterol: A drug for potential treatment of muscle wasting. Cancer Res 64, 6725-6731, 2004.
176. Beitzel F, Gregorevic P, Ryall JG, Plant DR, Sillence MN, et al.: Beta2-Adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury. J Appl Physiol 96, 1385-1392, 2004.
177. Kline WO, Panaro FJ, Yang H, and Bodine SC: Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. J Appl Physiol 102, 740-747, 2007.
178. Benson DW, Foley-Nelson T, Chance WT, Zhang FS, James JH, et al.: Decreased myofibrillar protein breakdown following treatment with clenbuterol. J Surg Res 50, 1-5, 1991.
179. Bohorov O, Buttery PJ, Correia JH, and Soar JB: The effect of the Beta2-Adrenergic agonist clenbuterol or implantation with oestradiol plus trenbolone acetate on protein metabolism in wether lambs. Br J Nutr 57, 99-107, 1987.
180. Maltin CA, Delday MI, and Reeds PJ: The effect of a growth promoting drug, clenbuterol, on fiber frequency and area in hind limb muscles from young male rats. Biosci Rep 6, 293-299, 1986.
181. Choo JJ, Horan MA, Little RA, and Rothwell NJ. Anabolic effects of clenbuterol on skeletal muscle are mediated by beta2-Adrenoceptor activation. Am J Physiol 263(1 Pt 1), E50-E56, 1992.
182. Reeds PJ, Hay SM, Dorwood PM, and Palmer RM: Stimulation of muscle growth by clenbuterol: lack of effect on muscle protein biosynthesis. Br J Nutr 56, 249-258, 1986.
183. Claeys MC, Mulvaney DR, McCarthy FD, Gore MT, Marple DN, et al.: Skeletal muscle protein synthesis and growth hormone secretion in young lambs treated with clenbuterol. J Anim Sci 67, 2245-2254, 1989.
184. Gagnon B and Bruera E: A review of the drug treatment of cachexia associated with cancer. Drugs 55, 675-688, 1998.
185. Lambert CP, Uc EY, and Evans WJ: b2-Adrenergic agonists in the treatment of muscle atrophy. Pharmacotherapy of cachexia, Hofbauer KG, Anker SD, Inui A, Nicholson JR (eds.). Boca Raton, FL: CRC Press, 2006, pp. 3311-3324.
186. Castle A, Yaspelkis BB 3rd, Kuo CH, and Ivy JL: Attenuation of insulin resistance by chronic beta2-Adrenergic agonist treatment: possible muscle specific contributions. Life Sci 69, 599-611, 2001.
187. Jeppsson AB, Waldeck B, and Widmark E: Further studies on the cardiomegaly induced by Beta-Adrenoceptor agonists. Acta Pharmacol Toxicol (Copenh) 58, 121-125, 1986.
188. Sleeper MM, Kearns CF, and McKeever KH: Chronic clenbuterol administration negatively alters cardiac function. Med Sci Sports Exercise 34, 643-650, 2002.
189. Fuster G, Busquets S, Ametller E, Olivan M, Almendro V, et al.: Are peroxisome proliferator-Activated receptors involved in skeletal muscle wasting during experimental cancer cachexia?. Role of Beta 2- adrenergic agonists. Cancer Res 67, 6512-6519, 2007.
190. Greig CA, Johns N, Gray C, MacDonald A, Stephens NA, et al.: Phase I/ II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy. Support Care Cancer 22, 1269-1275, 2014.
191. Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, et al.: The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: Results of a double-blind, placebocontrolled phase II trial. J Cachexia Sarcopenia Muscle 2, 153-161, 2011.
192. Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, et al.: Effects of enobosarm on muscle wasting and physical function in patients with cancer: A double-blind, randomised controlled phase2 trial. Lancet Oncol 14, 335-345, 2013.
193. Mantovani G and Madeddu C: Cancer cachexia: medical management. Support Care Cancer 18, 1-9, 2010.
194. Gullett NP, Hebbar G, and Ziegler TR: Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr 91, 1143S-1147S, 2010.
195. Akyurek M: Plastic Surgery Educational Foundation DATA Committee. Oxandrolone Plast Reconstr Surg 118, 791-794, 2006.
196. Orr R and Fiatarone Singh M: The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs 64, 725-750, 2004.
197. Lesser G: ASCO Meeting. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy. Proc Am Soc Clin Onc 26, 505s, 2008.
198. Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, et al.: A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 6, 18-25, 2008.
199. Jatoi A, Ritter HL, Dueck A, Nguyen PL, Nikcevich DA, et al.: A placebo-controlled, double-blind trial of infliximab for cancer-Associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 68, 234-239, 2010.
200. Gueta I, Altman A, Shoenfeld Y. The effect of blocking TNF-Alpha in patients with cancer-related cachexia and anorexia. Harefuah 149, 512-514, 551, 550, 2010.